Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Akeso is the lead sponsor of 79 current clinical trials in our China and USA registers. 38 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Ivonescimab, Cadonilimab and AK117. The most-studied condition is Hepatocellular Carcinoma.

ClinicalTrials.gov trials by status

Recruiting3848%
Not yet open2127%
Active, closed2025%

Trials by phase

Phase 22329%
Phase 32228%
Phase 1/21924%
Phase 11418%
Observational11%

Clinical trials sponsored by Akeso

79 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) NCT06530251 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: AK127, AK130, Bevacizumab biosimilar	Phase 1/2	Recruiting	2024-09	China
A Study of AK138D1 in Advanced Malignant Tumors NCT07281326 · ClinicalTrials.gov ↗ · Solid Cancer Drug: AK138D1	Phase 1	Recruiting	2025-10	China
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors NCT05868876 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1	Recruiting	2023-06	China
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma NCT04982276 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma Drugs: AK109, Cadonilimab, Paclitaxel	Phase 1/2	Recruiting	2021-08	China
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer NCT07669779 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer (NSCLC) Drugs: AK146D1, Ivonescimab, Osimertinib	Phase 2	Recruiting	2026-07	China
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer NCT06953999 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 3	Recruiting	2025-06	China
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer NCT07591090 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Drugs: AK146D1, Ivonescimab	Phase 2	Recruiting	2026-07	China
A Study of AK131 in Patients With Advanced Solid Tumors NCT06166888 · ClinicalTrials.gov ↗ · Solid Tumor Drug: AK131	Phase 1	Recruiting	2024-01	China
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	2025-07	China
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes NCT06196203 · ClinicalTrials.gov ↗ · Higher-risk Myelodysplastic Syndromes Drugs: AK117, Azacitidine	Phase 2	Recruiting	2024-02	USA, China
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors NCT05689853 · ClinicalTrials.gov ↗ · Solid Tumor, Adult Drugs: AK119, Ivonescimab	Phase 1/2	Recruiting	2023-04	China
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection NCT05489289 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drug: Cadonilimab	Phase 3	Recruiting	2023-01	China
AK104 for Recurrent or Metastatic Vulvar Cancer NCT05932212 · ClinicalTrials.gov ↗ · Vulvar Cancer Drugs: Cadonilimab, Carboplatin, Cisplatin	Phase 2	Recruiting	2023-08	China
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer NCT07114315 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: AK130, Ivonescimab	Phase 2	Recruiting	2025-09	China
A Study of AK129 in Patients With Advanced Malignant Tumors NCT05645276 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors(Stage IA-IB)	Phase 1	Recruiting	2023-03	China
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer NCT07412613 · ClinicalTrials.gov ↗ · Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer Drugs: Cadonilimab, Calcium folinate, Capecitabine	Phase 3	Recruiting	2026-04	China
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors NCT05142423 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: AK109, Cadonilimab	Phase 1/2	Recruiting	2021-11	China
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer NCT05859750 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: 5-Fluorouracil/Leucovorin, Cadonilimab, Gemcitabine	Phase 2	Recruiting	2023-05	China
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. NCT07052253 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC) Drugs: Cadonilimab, Ivonescimab, Tinengotinib	Phase 2	Recruiting	2025-07	China
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer NCT06686030 · ClinicalTrials.gov ↗ · Platinum-sensitive Ovarian Cancer Drugs: Ivonescimab, Olaparib	Phase 2	Recruiting	2025-02	China
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC) Drugs: Ivonescimab, Nab-paclitaxel	Phase 3	Recruiting	2025-02	China
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma NCT05960955 · ClinicalTrials.gov ↗ · Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	2023-11	China
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer NCT07623356 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: AK138D1, Carboplatin, Ivonescimab	Phase 1/2	Recruiting	2026-07	China
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma NCT06341335 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	2024-06	China
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104) NCT07547787 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Gastric Cancer	Observational	Recruiting	2024-12	China
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) NCT07263919 · ClinicalTrials.gov ↗ · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Drugs: Cadonilimab, Cisplatin, Paclitaxel	Phase 2	Recruiting	2025-12	China
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma NCT06371157 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Cadonilimab, Lenvatinib	Phase 3	Recruiting	2024-08	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma Drugs: Afatinib, Carboplatin, Cetuximab	Phase 1/2	Recruiting	2025-05	China
A Study of AK146D1 for Injection in Advanced Solid Tumors NCT07067567 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: AK146D1	Phase 1	Recruiting	2025-08	China
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma NCT07023315 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Drug: Cadonilimab	Phase 3	Recruiting	2025-08	China
A Study of Ivonescimab in First-Line ES-SCLC NCT07245446 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 2	Recruiting	2025-10	China
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) NCT06601335 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drugs: AK117, Ivonescimab	Phase 3	Recruiting	2024-10	China
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer NCT06938321 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: AK130, Ivonescimab	Phase 1/2	Recruiting	2025-04	China
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy NCT07010263 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drug: Ivonescimab	Phase 3	Recruiting	2025-06	China
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC NCT06617416 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer) Drugs: Cadonilimab, Sugemalimab	Phase 3	Recruiting	2024-11	China
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma NCT06642792 · ClinicalTrials.gov ↗ · Classic Hodgkin Lymphoma Drugs: Afatinib, AK117	Phase 1/2	Recruiting	2025-01	China
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer NCT06951503 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma Drugs: Bevacizumab, Irinotecan, Ivonescimab	Phase 3	Recruiting	2025-05	China
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer NCT06560112 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer Drugs: Cadonilimab, Ivonescimab	Phase 2	Recruiting	2024-11	China
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer NCT07560124 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: AK138D1, Ivonescimab	Phase 1/2	Not yet open	2026-06	China
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment NCT07158840 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: Ivonescimab	Phase 2	Not yet open	2025-09	China
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC NCT06913218 · ClinicalTrials.gov ↗ · Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma Drugs: Cadonilimab, Ivonescimab, Ivonescimab (SMT112	Phase 1	Not yet open	2025-07	China
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma NCT07436221 · ClinicalTrials.gov ↗ · Asthma Drug: AK139	Phase 2	Not yet open	2026-02	China
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) NCT06756126 · ClinicalTrials.gov ↗ · Atopic Dermatitis	Phase 2	Not yet open	2024-12	China
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma NCT07636772 · ClinicalTrials.gov ↗ · Urothelial Carcinoma (UC) Drugs: AK146D1, Ivonescimab	Phase 2	Not yet open	2026-06	China
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma NCT06586294 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 1/2	Not yet open	2024-09	China
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps NCT07755371 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Drug: AK139	Phase 2	Not yet open	2026-08	China
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis NCT06767540 · ClinicalTrials.gov ↗ · Atopic Dermatitis	Phase 3	Not yet open	2025-01	China
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma NCT07700979 · ClinicalTrials.gov ↗ · Gastric / Gastroesophageal Junction Adenocarcinoma Drugs: Cadonilimab, Capox, Nivolumab	Phase 3	Not yet open	2026-08	USA, China
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases NCT07357220 · ClinicalTrials.gov ↗ · Colorectal Cancer With Hepatic Metastases Drugs: Ivonescimab, VG2025	Phase 1/2	Not yet open	2026-03	China
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects NCT06641388 · ClinicalTrials.gov ↗ · Healthy Subjects (HS)	Phase 1	Not yet open	2024-11	China
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors NCT06691360 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1	Not yet open	2024-12	China
A Clinical Study of AK139 in Healthy Subjects NCT06947109 · ClinicalTrials.gov ↗ · Healthy Subjects	Phase 1	Not yet open	2025-05	China
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) NCT06860789 · ClinicalTrials.gov ↗ · Chemotherapy-induced Peripheral Neuropathy (CIPN)	Phase 1	Not yet open	2025-02	China
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia NCT06387420 · ClinicalTrials.gov ↗ · ACUTE MYELOID LEUKEMIA; AML Drugs: AK117, Azacitidine, Venetoclax	Phase 1/2	Not yet open	2024-04	China
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis NCT07436234 · ClinicalTrials.gov ↗ · Seasonal Allergic Rhinitis Drug: AK139	Phase 2	Not yet open	2026-03	China
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer NCT05990127 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC	Phase 3	Not yet open	2023-11	China
A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s Disease NCT07301502 · ClinicalTrials.gov ↗ · Alzheimer' s Disease	Phase 1	Not yet open	2025-12	China
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations NCT07619001 · ClinicalTrials.gov ↗ · Healthy Male Adults Participants Drug: Cadonilimab	Phase 1	Not yet open	2026-06	China
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor NCT07566247 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1	Not yet open	2026-04	China
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer NCT05904379 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer Drugs: Cadonilimab, Carboplatin, Docetaxel	Phase 1/2	Active, closed	2023-07	China
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NCT04736823 · ClinicalTrials.gov ↗ · NSCLC Drugs: Carboplatin, Docetaxel, Ivonescimab	Phase 2	Active, closed	2021-02	China
A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects NCT07340476 · ClinicalTrials.gov ↗ · Healthy Male Subjects Drug: Ivonescimab	Phase 1	Active, closed	2025-12	China
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC NCT05247684 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	2022-02	China
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer NCT05227664 · ClinicalTrials.gov ↗ · Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer Drugs: AK117, Ivonescimab, Nab-paclitaxel	Phase 2	Active, closed	2022-03	China
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer NCT05846867 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: AK119, Calcium folinate, Fluorouracil	Phase 1/2	Active, closed	2023-05	China
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma NCT04974398 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma Drug: Penpulimab	Phase 3	Active, closed	2021-08	USA, China
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer NCT05382442 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: AK117, Capecitabine, Irinotecan	Phase 2	Active, closed	2022-06	USA, China
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer NCT06646055 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1/2	Active, closed	2025-01	China
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome NCT04900350 · ClinicalTrials.gov ↗ · Myelodysplastic Syndrome Drugs: AK117, Azacitidine	Phase 1/2	Active, closed	2021-06	China
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC NCT05319431 · ClinicalTrials.gov ↗ · Unresectable, Non-metastatic Hepatocellular Carcinoma Drugs: Cadonilimab, Lenvatinib	Phase 2	Active, closed	2022-06	China
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors Drugs: AK117, Carboplatin, Cisplatin	Phase 1/2	Active, closed	2022-05	China
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer NCT06591520 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Active, closed	2024-10	China
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia NCT04980885 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: AK117, Azacitidine	Phase 1/2	Active, closed	2021-08	China
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer NCT05235516 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Carcinoma Drugs: Cadonilimab, Cisplatin	Phase 3	Active, closed	2022-06	China
Phase 3 Clinical Study of AK112 for NSCLC Patients NCT05184712 · ClinicalTrials.gov ↗ · Non-Squamous Non-small Cell Lung Cancer Drugs: Ivonescimab, Ivonescimab (SMT112	Phase 3	Active, closed	2022-01	China
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer NCT05840016 · ClinicalTrials.gov ↗ · Advanced Squamous Non Small Cell Lung Cancer	Phase 3	Active, closed	2023-08	China
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer NCT04982237 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	2021-08	China
AK112 in Advanced Non-Small Cell Lung Cancer NCT05499390 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer	Phase 3	Active, closed	2022-11	China
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors NCT05951608 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: AK127, Ivonescimab	Phase 1/2	Active, closed	2023-10	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Akeso trials

43 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 3 more in the trial list above.

Conditions in Akeso trials

72 conditions

Hepatocellular Carcinoma3 Non-Small Cell Lung Cancer3 Advanced Malignant Tumors3 Pancreatic Cancer3 Advanced Solid Tumors3 Advanced Non-small-cell Lung Cancer2 Atopic Dermatitis2 Biliary Tract Cancer2Colorectal Adenocarcinoma2Nasopharyngeal Carcinoma1 Metastatic Colorectal Cancer1Higher-risk Myelodysplastic Syndromes1Gastric / Gastroesophageal Junction Adenocarcinoma1Breast Cancer1Solid Cancer1Pancreas Cancer1Pancreas Cancer, Duct Cell Adenocarcinoma1Asthma1 NSCLC1Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma1Advanced Non Small Cell Lung Cancer (NSCLC)1Healthy Male Subjects1Urothelial Carcinoma (UC)1Resectable Non-small Cell Lung Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in China	79	38
Clinical trials in USA	4	1

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Hepatocellular Carcinoma

Sponsor	Trials
Sun Yat-sen University	23
The First Affiliated Hospital with Nanjing Medical University	4
Chinese PLA General Hospital	4
Fujian Provincial Hospital	3
Shanghai Junshi Bioscience	3
Zhongda Hospital	3
Guangxi Medical University	3
Replimune	2
HistoSonics	2
Teclison	2

Sponsors with the most current trials registered for this condition.

Questions about Akeso trials

How many clinical trials does Akeso sponsor?

Akeso is the lead sponsor of 79 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Akeso trials recruiting?

Yes. 38 of its 79 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Akeso testing?

Its current trials name 43 drugs and biologicals as interventions. The most frequent are Ivonescimab (30), Cadonilimab (19), AK117 (9), Paclitaxel (7) and Carboplatin (6). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Akeso clinical trials